KANAMYCIN

Possibly Marketed Outside US

First approved in 2022

Description
Sources: http://www.rxlist.com/kantrex-drug/indications-dosage.htm
Curator's Comment: Description was created based on several sources, including: http://www.drugs.com/cdi/kanamycin.html https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d4865638-1259-4eef-a73c-fe919af6e850

Kanamycin (a mixture of kanamycin A, B and C) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. It is effective against Gram-negative bacteria and certain Gram-positive bacteria. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Serious side effects include tinnitus or loss of hearing, toxicity to kidneys, and allergic reactions to the drug. Mixing of an aminoglycoside with beta-lactam-type antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation. Even when an aminoglycoside and a penicillin-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial 70S ribosome 180 Target ID: CHEMBL2363135 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d4865638-1259-4eef-a73c-fe919af6e850	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Staphylococcal infections 24 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d4865638-1259-4eef-a73c-fe919af6e850	Curative		Approved 8583	KANAMYCIN SULFATE Approved Use Kanamycin may be considered as initial therapy in the treatment of infections where one or more of the following are the known or suspected pathogens: E. coli, Proteus species (both indole-positive and indole-negative), Enterobacter aerogenes, Klebsiella pneumoniae, Serratia marcescens, Acinetobacter species. Although kanamycin is not the drug of choice for staphylococcal infections, it may be indicated under certain conditions for the treatment of known or suspected staphylococcal disease. Launch Date 2002
Gram-negative bacterial infections 4 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d4865638-1259-4eef-a73c-fe919af6e850	Curative		Approved 8583	KANAMYCIN SULFATE Approved Use Kanamycin may be considered as initial therapy in the treatment of infections where one or more of the following are the known or suspected pathogens: E. coli, Proteus species (both indole-positive and indole-negative), Enterobacter aerogenes, Klebsiella pneumoniae, Serratia marcescens, Acinetobacter species. Although kanamycin is not the drug of choice for staphylococcal infections, it may be indicated under certain conditions for the treatment of known or suspected staphylococcal disease. Launch Date 2002

C_max

Value	Dose	Co-administered	Analyte	Population
11.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4790604/	250 mg single, intramuscular dose: 250 mg route of administration: Intramuscular experiment type: SINGLE co-administered:		KANAMYCIN A plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
44.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4790604/	250 mg single, intramuscular dose: 250 mg route of administration: Intramuscular experiment type: SINGLE co-administered:		KANAMYCIN A plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4790604/	250 mg single, intramuscular dose: 250 mg route of administration: Intramuscular experiment type: SINGLE co-administered:		KANAMYCIN A plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B1-01366	http://www.3bsc.com/index/pro_info.php?id=21578
3B Scientific (Wuhan) Corp	3B3-056685	http://www.3bsc.com/index/pro_info.php?id=95195
abcr GmbH	AB530401	http://www.abcr.com/shop/en/AB530401
Achemtek	0102-014506	http://www.achemtek.com/59-01-8
Acorn PharmaTech	ACN-043785	http://www.acornpharmatech.com/
AHH Chemical co.,ltd	MT-53022	http://www.ahhchemical.com/product/MT-53022.html
AK Scientific, Inc. (AKSCI)	K434	http://www.aksci.com/item_detail.php?cat=K434
Aurora Fine Chemicals LLC	A17.877.859	http://online.aurorafinechemicals.com/info?ID=A17.877.859
Aurora Fine Chemicals LLC	A17.912.896	http://online.aurorafinechemicals.com/info?ID=A17.912.896
Aurum Pharmatech LLC	KM0269	http://www.Aurumpharmatech.com/Product/ProductDetails/KM0269
BioCyc	CPD-4821	https://biocyc.org/compound?orgid=META&id=CPD-4821
BioSynth	K-0250	https://www.biosynth.com/en/products/life-science/culture-media-additives/products/K-0250.html
BioSynth	Q-201264	https://www.biosynth.com/en/products/life-science/culture-media-additives/products/Q-201264.html
BLD Pharm	BD00829212	http://www.bldpharm.com/products/59-01-8.html
Boerchem	BC678130	http://www.boerchem.com/?product_39692.html
ChemFish Tokyo co.,ltd	24721551	http://www.chemfish.co.jp/index.php?id=4632&project=product
ChemMol	30114547	http://www.chemmol.com/chemmol/30114547.html
ChemMol	44010165	http://www.chemmol.com/chemmol/44010165.html
ChemMol	99115243	http://www.chemmol.com/chemmol/99115243.html
ChemMol	99123582	http://www.chemmol.com/chemmol/99123582.html
Chemspace	CSSB00020617760	https://chem-space.com/CSSB00020617760
Clearsynth	CS-AD-00479	http://www.clearsynth.com/en/CSAD00479.html
Clearsynth	CS-O-30615	http://www.clearsynth.com/en/CSO30615.html
eNovation Chemicals	D669558	https://www.enovationchem.com/ProductDetails.asp?ProductID=D669558
Glentham Life Sciences	GA8523	http://www.glentham.com/products/product/GA8523/
Hairui	HR101443	http://www.hairuichem.com/en/product/64013-70-3.html
Hairui	HR127109	http://www.hairuichem.com/en/product/8063-07-8.html
iChemical	EBD3062805	http://www.ichemical.com/products/64013-70-3.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
iChemical	EBD5760	http://www.ichemical.com/chemicals/cas-8063-07-8
Lab Network	LN01345669	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01345669
MuseChem	I011452	https://www.musechem.com/product/I011452.html
MuseChem	R001542	https://www.musechem.com/product/R001542.html
Parchem	88189	https://www.parchem.com/chemical-supplier-distributor/Kanamycin-088189.aspx
Sigma-Aldrich	K0129_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/k0129?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	K0254_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/k0254?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	K1876_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/k1876?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S531583	http://www.smolecule.com/products/s531583
THE BioTek	bt-271566	https://www.thebiotek.com/product/inhibitors/bt-271566
THE BioTek	bt-361993	https://www.thebiotek.com/product/others/bt-361993
Yuhao Chemical	YH19615	http://www.chemyuhao.com/8063-07-8.html

PubMed

Title	Date	PubMed
Chlorinated coumarins from the polypore mushroom Fomitopsis officinalis and their activity against Mycobacterium tuberculosis.	2013-10-25	24087924
Mitochondrial peroxiredoxin 3 regulates sensory cell survival in the cochlea.	2013	23626763
Potent activity against multidrug-resistant Mycobacterium tuberculosis of α-mangostin analogs.	2013	23150066
Dominant incidence of multidrug and extensively drug-resistant specific Mycobacterium tuberculosis clones in Osaka Prefecture, Japan.	2012	22952596
Conservation of endocochlear potential in mice with profound hearing loss induced by co-administration of kanamycin and furosemide.	2011-04	21216844
Amyloid-like protein inclusions in tobacco transgenic plants.	2010-10-26	21049018
[Drug-induced nephropathy and hemorrhagic cystitis as an adverse reaction to kanamycin].	1989-08	2811228
Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosis.	1989-08	2478073
[Prevention of neurosensory hearing disorders in antibiotic-induced ototoxicosis].	1989-03-01	2728176
[Acute renal failure caused by ceporin, kanamycin and gentamicin].	1989-03-01	2728142
New antibiotics, resorcinomycins A and B: antibacterial activity of resorcinomycin A against mycobacteria in vitro.	1989-03	2708139
Nephrotoxicity of dactimicin, a novel pseudo-disaccharide aminoglycoside possessing the N-formimidoyl group, compared with that of astromicin, amikacin and other aminoglycoside antibiotics in animals.	1989	2791871
MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs.	1988-08	2461162
[Bilateral deafness after intra-lumbar administration of kanamycin].	1988-07-01	3218431
Qualitative and quantitative drug-susceptibility tests in mycobacteriology.	1988-05	3195815
Action of antituberculous and beta-lactam drugs (including imipenem) against extra- and intra-cellularly growing Mycobacterium avium-intracellulare.	1988-03-01	3165640
[Experimental study of drug-induced acute renal failure. Recovery after renal impairment caused by the administration of low molecular weight dextran and kanamycin in water-deprived rats].	1988-02	2454017
In vitro susceptibility of Mycobacterium avium complex to antibacterial agents.	1987-11	3440370
Determination of MICs of conventional and experimental drugs in liquid medium by the radiometric method against Mycobacterium avium complex.	1987	3428133
Mycobacterial plasmids: screening and possible relationship to antibiotic resistance in Mycobacterium avium/Mycobacterium intracellulare.	1986	3540539
[Measurement of an auditory impairment induced by aminoglycosides using a shuttle box method in newborn rats].	1985-12	4093075
Reflex modification as a test for sensory function.	1985-11-01	3835474
Furosemide ototoxicity: clinical and experimental aspects.	1985-09	4033342
In vitro antituberculosis activity of a new antibacterial substance ofloxacin (DL8280).	1985-03	3919625
Nephrotoxic effects of aminoglycoside treatment on renal protein reabsorption and accumulation.	1984	6728084
[Detection of auditory impairment in the offsprings caused by drug treatment of the dams].	1982-12	6186586
In vitro susceptibility of Mycobacterium avium complex and Mycobacterium tuberculosis strains to a spiro-piperidyl rifamycin.	1982-09	6289711
Potentiation of neuromuscular weakness in infant botulism by aminoglycosides.	1979-12	501488
Quantitative relationships of the ototoxic interaction of kanamycin and ethacrynic acid.	1979-05	435146
Auditory thresholds and kanamycin-induced hearing loss in the guinea pig assessed by a positive reinforcement procedure.	1978-02	670552
[Amikacin and kanamycin. Comparative experimental studies on nephrotoxicity].	1978	580391
Drug-induced anaphylaxis, convulsions, deafness, and extrapyramidal symptoms.	1977-03-12	65671
[On the mechanism of kanamycin ototoxicity (II): --Alteration of glucose metabolism in cochlea and kidney (author's transl)].	1977-01-20	557540
Proceedings: The use of conditioned tone discrimination to study kanamycin ototoxicity in the rat.	1975-12	2689
The quantification of kanamycin ototoxicity in the rat using conditioned tone discrimination.	1975-12	2661
Nephropathy, an underestimated complication of methicillin therapy.	1974-06	4826627
Protein synthesis in Mycobacterium tuberculosis H37Rv and the effect of streptomycin in streptomycin-susceptible and -resistant strains.	1973-09	4202339
Laboratory testing for ototoxic effects of drugs.	1973-06	4733734
Acute renal failure in general surgical patients.	1971-06	5314126
[Biochemical studies on nephrotoxicity of kanamycin].	1971-02	5102025
[Severe hearing disorders caused by kanamycin].	1970-09	5460124
[Hearing damages in prolonged kanamycin therapy].	1970-08	5314873
[Studies on nephrotoxicity of combined administration of kanamycin and sodium alginate].	1970-06	5464695
Kanamycin ototoxicity--possible potentiation by other drugs.	1970-05	5446818
[Recovery after hemodialysis in 2 cases of acute renal insufficiency during treatment with kanamycin and colistin methanesulfonate].	1970-04-27	5419940
[Clinical studies of cochleotoxicosis due to viomycin and kanamycin during tuberculostatic treatment (a prophylactic attempt)].	1968	4302952
Experimental studies on therapeutic effects of various combinations of antituberculosis drugs. II. Comparison of various regimens in treatment of experimental mouse tuberculosis infected with SM- and INH-resistant Schacht strain.	1967-07	4295381
Unusual neurotoxicity of kanamycin.	1967-05-01	6071516
Rifampicin: a new rifamycin. II. Laboratory studies on the antituberculous activity and preliminary clinical observations.	1967-05	5631580
[Clinical use of vitamin K-1 in hearing disorders caused by kanamycin].	1966-04	6006474

Patents

Sample Use Guides

In Vivo Use Guide

Intramuscular and intravenous: 15 mg/kg/day in two equally divided dosages. Intraperitoneal: 500 mg diluted in 20 mL sterile distilled water may be instilled through a polyethylene catheter sutured into the wound at closure. Aerosol treatment: 250 mg two to four times a day. Irrigation: injection in concentrations of 0.25 percent (2.5 mg/mL).

Route of Administration: Other

In Vitro Use Guide

The minimum inhibitory concentration (MIC), determined by the microdilution method, of E. coli and S. aureus were 4.5 and 3.5 mg/L, respectively. The MIC was 5.0 mg/L for the dual species scenario.

Substance Class	Mixture Created by `admin` on `Mon Mar 31 18:28:47 GMT 2025` Edited by `admin` on `Mon Mar 31 18:28:47 GMT 2025`
Record UNII	RUC37XUP2P
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

KANAMYCIN

Official Name

English

ANTIBIOTIC COMPLEX FROM STREPTOMYCES KANAMYCETICUS CONTAINING KANAMYCIN A (MAJOR), KANAMYCIN B AND KANAMYCIN C

Preferred Name

English

KANAMYCIN [VANDF]

Common Name

English

Kanamycin [WHO-DD]

Common Name

English

KANAMYCIN [HSDB]

Common Name

English

KANAMYCINS

Common Name

English

KANAMYCIN [MI]

Common Name

English

kanamycin [INN]

Common Name

English

Classification Tree Code System Code

CFR

21 CFR 524.1204